Related Experiment Video
Updated: Oct 14, 2025
06:44
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.6K
Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report
Yoshitaka Saito1, Yoh Takekuma1, Takashi Takeshita2
1Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan.
Case Reports in Oncology
|November 1, 2021
Summary
Docetaxel chemotherapy can cause severe hypertriglyceridemia in breast cancer patients. Fibrates effectively managed this side effect, highlighting the need for monitoring lipid levels during treatment.
Area of Science:
- Oncology
- Pharmacology
- Endocrinology
Background:
- Docetaxel (DOC) is a key chemotherapy agent for breast cancer.
- Hypertriglyceridemia is a potential, though uncommon, side effect of DOC.
- Patient had pre-existing controlled hyperlipidemia and HER2-overexpressing stage IIB breast cancer.
Observation:
- A patient receiving DOC, pertuzumab, and trastuzumab developed Grade 3 hypertriglyceridemia (770 mg/dL).
- This occurred after the third cycle of neoadjuvant chemotherapy, without overt symptoms.
- Baseline triglyceride levels were mildly elevated but controlled.
Findings:
- Docetaxel-induced severe hypertriglyceridemia was strongly suspected.
- Sustained-release bezafibrate administration rapidly normalized triglyceride levels.
- Lipid levels remained stable post-treatment with bezafibrate cessation and during adjuvant therapy.
Implications:
- Docetaxel can precipitate severe hypertriglyceridemia, necessitating vigilant monitoring of lipid profiles.
- Fibrate therapy is an effective intervention for managing this adverse event.
- Further research into the mechanisms and risk factors is crucial for optimizing patient management and preventing complications.
